Immunotherapies for emergency situations
Treatments for emerging infectious diseases and biodefense solutions.
Technology
Fab’entech is specialised in the development of polyclonal antibody treatments against emerging infectious diseases, and in the development of bio defence solutions.
This technology, initially developed by Sanofi Pasteur, has been enhanced by the Fab’entech R&D teams for more than a decade.
Polyclonal antibodies recognise then neutralise the virus or toxin in a few minutes, stop the worsening of the disease, and therefore protect the patient’s life.
Traitements
Bio defence
Fab’entech benefits from the confidence of the DGA (General Directorate of Armaments)for the production of biodefense solutions
Emerging infectious diseases
Fab’entech’s COVID-19 programme is one of 20 priority projects selected by the government to fight COVID-19
Drug intoxications
The technology used makes it possible to design treatments that are adapted to the management of drug intoxications
Infectious diseases
Fab’entech develops treatments intended for patients that are already infected and who are at risk of developing serious forms of the disease
Pipeline
Treatment
Proof of Concept
Preclinical stage
clinical
stage
development completed
FabenFLU ® - H5N1
FabenCOV ® - COVID-19
ANTIDOTE #1 Bio defence
EBOLA
ANTIDOTE #2 Infectious diseases
